Get the Stockscreener App
0.6251
10.33%
0.045
Galmed Pharmaceuticals Ltd stock is traded at $0.6251, with a volume of 71,570.
It is up +10.33% in the last 24 hours and up +2.09% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
See More
Previous Close:
$0.5801
Open:
$0.5775
24h Volume:
71,570
Relative Volume:
0.03
Market Cap:
$4.16M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-0.2682
EPS:
-2.3308
Net Cash Flow:
$-6.32M
1W Performance:
+11.36%
1M Performance:
+2.09%
6M Performance:
-30.72%
1Y Performance:
-53.96%
1-Day Range:
$0.575
$0.6554
1-Week Range:
$0.5683
$0.6554
52-Week Range:
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.6301 | 3.83M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
436.98 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.25 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.37 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.66 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.69 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
GLMD Should I Buy - Intellectia AI
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
GLMD Q1'26 Earnings: EPS estimate is (0.38) USD - TradingView
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Number of shareholders of Galmed Pharmaceuticals Ltd. – FWB:GPH - TradingView
Galmed Pharmaceuticals Ltd.Ordinary Shares (NQ: GLMD - FinancialContent
Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation - TipRanks
Galmed reports improved bioavailability in Aramchol study - Investing.com
Galmed reports improved bioavailability in Aramchol study By Investing.com - Investing.com Australia
Aramchol PK study shows fivefold exposure gain, Galmed (NASDAQ: GLMD) says - Stock Titan
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PR Newswire
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Australia
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
Galmed (NASDAQ: GLMD) teams with Tissue Dynamics on chronic cardiac fibrosis platform - Stock Titan
Tissue Dynamics, Galmed partner on cardiac fibrosis model - Investing.com
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Fast Moving Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Galmed collaborates with Tel Aviv University to evaluate targeted therapy for metastatic brain cancers - BioSpectrum Asia
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed partners with Tel Aviv University on brain cancer therapy - Investing.com
Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer - TipRanks
Galmed (NASDAQ: GLMD) and Tel Aviv University test Aramchol for brain cancer - Stock Titan
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PR Newswire
GLMD SEC FilingsGalmed Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Galmed stock soars on brain-penetrating Aramchol formulation - MSN
Galmed Stock Soars On Brain-Penetrating Aramchol FormulationGalmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases - TipRanks
Galmed Pharmaceuticals Maps Future with Aramchol Strategy - timothysykes.com
GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy? - Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - The AI Journal
Is Galmed Pharmaceuticals (GLMD) Stock a Safe Investment | Price at $0.52, Down 1.03%Call Resistance - Newser
[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan
Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan
MEDIA ADVISORY – Minister LeBlanc, Secretary of State Long and Parliamentary Secretary Myles to highlight investments supporting the Canadian Armed Forces following achievement of the NATO 2% defence spending target - Weekly Voice
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - ChartMill
Ideas Watch: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2026 Update & Entry and Exit Point Strategies - baoquankhu1.vn
Portfolio Update: Can Galmed Pharmaceuticals Ltd grow without dilution2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):